 Home > Active Pharmaceutical Ingredients > Other Chemical Drugs > Retatrutide Reta retatrutide

Retatrutide Reta retatrutide

TDS

Unit Price: Get Latest Price 

Content:

99%

Port:

China

Packaging:

1kg/bag

Price valid (until):

2026-05-22

Contact Supplier

 Chat Now

Hangzhou Fullas Pharmatech Co.,Ltd.

Company Type:

Distributor

Location:

China

Qualification:

Main Products:

GLP-1,Tirzepatide,Retatrutide,MOTS-c

 Visit Store

Product Description
Seller Information

Description

Retatrutide (USAN, INN; code LY3437943; CAS 2381089-83-2) is a synthetic 39-amino acid peptide with the molecular formula C₂₂₁H₃₄₂N₄₆O₆₈ and a molecular weight of approximately 4731.3 g/mol. Engineered from a GIP backbone, it incorporates three non-coded residues (Aib², α-Me-Leu¹³, Aib²⁰) and features a C20 fatty diacid conjugated via a γ-glutamic acid and AEEA linker, enabling reversible albumin binding for extended half-life, with an amidated C-terminus. As a first-in-class unimolecular triple agonist, Retatrutide simultaneously targets the glucose-dependent insulinotropic polypeptide receptor (GIPR), glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR), thereby integrating complementary metabolic actions: GIPR and GLP-1R activation enhances glucose-dependent insulin secretion and suppresses appetite, while GCGR agonism increases energy expenditure and directly promotes lipolysis, resulting in superior glycemic control and weight loss compared to dual agonists.

Certificates
- TDS
Basic Info

Product Name:
Retatrutide Reta retatrutide

Categories:
Other Chemical Drugs

Research

Class:
Triple agonist — GCGR, GIPR, GLP-1R

Status:
Investigational (Phase 3)

Mechanism:
Simultaneously activates glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Engineered from the native GIP backbone with amino acid substitutions to confer GCGR and GLP-1R activity.

EC50 (Human GCGR):
5.79 nM

EC50 (Mouse GIPR):
0.191 nM

EC50 (Mouse GLP1R):
0.794 nM

EC50 (Mouse GCGR):
2.32 nM

EC50 (Human GLP1R):
0.775 nM

EC50 (Human GIPR):
0.0643 nM

Source:
Jastreboff AM, et al. N Engl J Med. 2023;389(6):514-526.DOI

Clinical Development:
NCT04881760; NCT05882045; NCT06354660

References

ChEMBL:
CHEMBL5095485

DrugBank:
DB18993

KEGG DRUG:
D12430

PubChem:
PubChem

Literature:
NEJM: Jastreboff et al. (2023) — Phase 2 Trial; FDA Drugs@FDA

Disclaimer:
Retatrutide is an investigational compound not yet approved by FDA or EMA. This listing is for industrial and laboratory research use only. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
Seller Information

Business Type:
Distributor

Main Products:
GLP-1,Tirzepatide,Retatrutide,MOTS-c

Location:
5 Euro America Financial City EFC Yuhang District Hangzhou China 311100 P.R.China

Payment Terms:
TT against copy of documents,L/C,TT against B/L draft before shipment

Average lead Time:
1

Year of Establishment:
2023
Country Product Purchase Quantity Date Posted

Post an enquiry for this product

Retatrutide Reta retatrutide

Product Description

Seller Information

Related Products

Related Searches